

FY2023 Financial Results Presentation

DAIICHI SANKYO CO., LTD.

Hiroyuki Okuzawa

Representative Director, President & COO

April 25, 2024

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward-looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.


This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

Agenda

- 1 FY2023 Financial Results**
- 2 Business Update
- 3 R&D Update
- 4 5-Year Business Plan Update
- 5 FY2024 Forecast
- 6 Appendix



Overview of FY2023 Results

(Bn JPY)

		FY2022 Results	FY2023 Results	YoY	
Revenue		1,278.5	1,601.7	+25.3%	323.2
Cost of sales *1		349.1	414.8		65.7
SG&A expenses *1		470.1	627.3		157.2
DXd ADC profit share *2		90.8	170.6		79.8
Other SG&A expenses		379.3	456.8		77.5
R&D expenses *1		336.7	364.3		27.6
Core operating profit *1		122.6	195.3	+59.3%	72.7
Temporary income *1		21.9	27.3		5.4
Temporary expenses *1		23.9	10.9		-13.0
Operating profit		120.6	211.6	+75.5%	91.0
Profit before tax		126.9	237.2		110.4
Profit attributable to owners of the Company		109.2	200.7	+83.8%	91.5
Currency	USD/JPY	135.48	144.62		+9.14
Rate	EUR/JPY	140.97	156.79		+15.82


*1 As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed. Income and expenses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses". Temporary income and expenses are excluded from results and forecast for cost of sales, SG&A expenses and R&D expenses shown in the list above. The adjustment table from operating profit to core operating profit is stated in the reference data.

*2 DS pays alliance partners 50% of gross profit for the product sales in countries/regions where DS book revenue (excluding Japan) to share profit with the partners.

Revenue

Increased by 323.2 Bn JPY (Increased by 256.4 Bn JPY excl. forex impact)

(Bn JPY)



Positive Factors

Japan Business Unit

Inavir	+15.0
Enhertu	+12.2
Lixiana	+10.4
Tarlige	+7.2
Vacciness Business	+14.3

Oncology Business Unit*1

Enhertu	+125.1
Vanflyta	+1.7

American Regent Unit

Venofer	+5.7	Injectafer	-7.1
GE injectables	+4.3		

EU Specialty Business Unit

Lixiana	+14.3	Olmesartan	-2.4
Nilemdo/Nustendi	+9.5		

ASCA (Asia, South and Central America) Business Unit

Enhertu	+25.4
Lixiana	+3.8

Upfront Payment & Regulatory/Sales Milestone etc. related to alliance with AstraZeneca and MRK*2

Enhertu Sales Milestone	+16.5	Enhertu Regulatory Milestone	-14.3
Upfront Payment from MRK	+12.9		

*1 Revenue for Daiichi Sankyo, Inc. and Daiichi Sankyo Europe's oncology products

*2 Merck & Co., Inc., Rahway, NJ, USA

*3 Forex impact USD: +29.6, EUR: +29.0, ASCA: +8.2

Core Operating Profit

Increased by 72.7 Bn JPY (Increased by 62.1 Bn JPY excl. forex impact)

(Bn JPY)

FY2022 Results

122.6

Revenue

323.2

Cost of Sales

53.1

SG&A Expenses

131.0

R&D Expenses

10.2

Forex Impact

56.2

FY2023 Results

195.3

■ Positive Factors ■ Negative Factors

Revenue +323.2

incl. forex impact of +66.8

Cost of Sales +53.1

Increase in cost of sales due to the revenue increase

SG&A Expenses +131.0

Increase in profit share due to the Enhertu revenue expansion
Increase in expenses due to new indications for Enharts, and the launch preparation for Dato-DXd and HER3-DXd, etc.

R&D Expenses +10.2

Increase in 5DXd ADCs* R&D investments

Forex Impact +56.2 (Profit Decreased)

Cost of Sales +12.6


SG&A Expenses +26.2

R&D Expenses +17.4

Profit Attributable to Owners of the Company

Increased by 91.5 Bn JPY

(Bn JPY)



Temporary Income/Expenses +18.4 (Profit Increased)

	FY2022 Results	FY2023 Results	YoY
Temporary Income	21.9 ^{*1}	27.3 ^{*2}	+5.4
Temporary Expenses	23.9 ^{*3}	10.9 ^{*4}	-13.0

- *1 Gains related to sales of fixed assets of Kyushu Branch Building (8.1)
Gains related to sales of subsidiary of Daiichi Sankyo (China) (5.9)
Gains on reversal related to closure of Plexxikon (3.2)
- *2 Lump sum payment received from Novartis following the settlement of Plexxikon's patent infringement lawsuit (26.4)
- *3 Losses related to impairment of Intangible assets of Turalio (14.2), DS-5141 (6.3) etc.
- *4 Environmental expenditures related to former Yasugawa plant (4.1)

Financial Income/Expenses etc. +19.4 (Profit Increased)

- Increase in interest income +13.6
- Improvement in investment securities +6.2
valuation gains/losses

Income Taxes etc. +18.6 (Profit Decreased)

	FY2022 Results	FY2023 Results	YoY
Profit before Tax	126.9	237.2	+110.4
Income Taxes etc.	17.7	36.2	+18.6
Tax rate	13.9%	15.3%	+1.4%

Revenue: Business Units (incl. Forex Impact)

(Bn JPY)

	FY2022 Results	FY2023 Results	YoY
Japan Business	457.9	518.9	+61.0
Daiichi Sankyo Healthcare	70.3	76.0	+5.6
Oncolgy Business	185.4	334.6	+149.2
Enhertu	181.6	327.4	+145.8
Turalio	3.8	5.3	+1.5
American Regent	187.4	203.4	+16.1
Injectafer	54.0	50.1	-3.9
Venofer	51.3	60.9	+9.6
GE injectables	71.6	81.0	+9.4
EU Specialty Business	150.4	189.2	+38.8
Lixiana	117.1	146.2	+29.1
Nilemdo/Nustendi	7.1	18.4	+11.4
Olmesartan	20.0	19.6	-0.4
ASCA (Asia, South and Central America) Business	142.8	184.1	+41.3

Currency	USD/JPY	135.48	144.62	+9.14
Rate	EUR/JPY	140.97	156.79	+15.82

Revenue: Major Products in Japan

(Bn JPY)

		FY2022 Results	FY2023 Results	YoY
Lixiana	anticoagulant	105.1	115.6	+10.4
Pralia	treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis	40.2	42.8	+2.6
Tarlige	pain treatment	38.5	45.7	+7.2
Vimpat	anti-epileptic agent	21.9	25.7	+3.8
Ranmark	treatment for bone complications caused by bone metastases from tumors	20.4	20.4	-0.0
Tenelia	type 2 diabetes mellitus treatment	21.9	20.5	-1.5
Enhertu	anti-cancer agent (HER2-directed antibody drug conjugate)	11.7	23.9	+12.2
Efient	antiplatelet agent	20.9	25.6	+4.7
Canalia	type 2 diabetes mellitus treatment	16.3	15.9	-0.4
Loxonin	anti-inflammatory analgesic	18.5	15.5	-3.0
Emgality	prophylaxis of migraine attacks	6.3	7.6	+1.3
Inavir	anti-influenza treatment	0.9	15.9	+15.0

Agenda

- ① FY2023 Financial Results
- ② **Business Update**
- ③ R&D Update
- ④ 5-Year Business Plan Update
- ⑤ FY2024 Forecast
- ⑥ Appendix



Progress towards “Maximize 3ADCs”

Progress towards “Profit growth for current business and products”

Progress towards “Create shared value with stakeholders”

(Bn JPY)

	FY2023 Results		FY2024 Forecast		<Reference> Total Consideration
		YoY		YoY	
Product Sales	395.9	188.4	508.4	112.4	-
Japan	23.9	12.2	25.7	1.8	-
US	225.5	81.0	266.6	41.1	-
Europe	101.9	64.8	152.1	50.2	-
ASCA	44.6	30.4	64.0	19.4	-
Upfront payment	10.1 ^{*1}	0.3	10.2 ^{*1}	0.1	149.0
Regulatory milestone payment	12.4 ^{*1}	-14.3	9.4 ^{*1}	-2.9	137.7
US HER2+ Breast Cancer 3L	0.9	0.0	0.9	0.0	13.7
EU HER2+ Breast Cancer 3L	0.5	0.0	0.5	0.0	7.9
US HER2+ Gastric Cancer 2L + 3L	0.8	0.0	0.8	0.0	12.1
US HER2+ Breast Cancer 2L	0.9	-2.6	0.9	0.0	13.1
EU HER2+ Breast Cancer 2L	0.7	-2.0	0.7	0.0	10.1
US HER2-low Breast Cancer (post-chemo)	1.9	-5.4	1.9	0.0	27.7
EU HER2-low Breast Cancer (post-chemo)	1.3	-3.9	1.4	0.0	19.8
EU HER2+ Gastric Cancer 2L	0.3	-0.9	0.3	0.0	4.8
US HER2 Mutant NSCLC 2L	1.2	-3.4	1.2	0.0	17.3
EU HER2 Mutant NSCLC 2L	3.8	3.8	0.8	-3.0	11.1
Quid related payment	1.2 ^{*1}	0.0	1.2 ^{*1}	0.0	17.2
Sales milestone payment	29.6 ^{*3}	16.5	56.2 ^{*2} ^{*4}	26.6	42.8
Total	449.2	190.8	585.4	136.2	346.7

*1 Revenue recognized in each period

*2 Converted with assumed forex rate for FY2024 of 145 JPY to 1 USD

*3 Milestone of 200Mn USD for achieving annual product sales of 2 Bn USD in co-commercialization territory with AstraZeneca.
(Total amount to be recognized as revenue in FY2023)

*4 Milestone of 387.5Mn USD for achieving annual product sales of 3.5 Bn USD in co-commercialization territory with AstraZeneca.
(Total amount to be recognized as revenue in FY2024)

Global product sales: FY2023 results **395.9 Bn JPY** (YoY +188.4 Bn JPY) FY2024 forecast **508.4 Bn JPY** (YoY +112.4 Bn JPY)

US

◆ **Product sales:** FY2023 results **225.5 Bn JPY** (1,560 Mn USD) FY2024 forecast **266.6 Bn JPY** (1,839 Mn USD)

◆ **Indication:** HER2+ mBC 2L+, HER2 low mBC (post-chemo), HER2+ mGC 2L+, HER2 mutant mNSCLC 2L+,
HER2+ (IHC3+) Metastatic Solid Tumors 2L+

◆ **Market share status**

- HER2+ mBC 2L: Increasing No.1 new patient share
- HER2 low mBC: Maintaining No.1 new patient share
- HER2+ mGC 2L: Maintaining No.1 new patient share
- HER2 mutant mNSCLC 2L: Maintaining No.1 new patient share

◆ **Other progress**

- Classified in NCCN*1 guidelines: endometrial cancer (Sep. 2023), cervical cancer (Sep. 2023), head and neck cancer (Dec. 2023), ovarian cancer (Jan. 2024), [vaginal cancer \(Mar. 2024\)](#), [biliary tract cancer \(Apr. 2024\)](#)
- [Approved for HER2+ \(IHC3+\) Metastatic Solid Tumors 2L+ and started promotion \(Apr. 2024\)](#)

Europe

◆ **Product sales:** FY2023 results **101.9 Bn JPY** (704 Mn USD) FY2024 forecast **152.1 Bn JPY** (1,049 Mn USD)


◆ **Indication:** HER2+ mBC 2L+, HER2 low mBC (post-chemo), HER2+ mGC 2L+, HER2 mutant mNSCLC 2L+

◆ **Market share status**

- HER2+ mBC 2L: Maintaining No.1 new patient share in France, Germany, Spain and Italy, and [increasing new patient share](#)
- HER2 low mBC : Maintaining No.1 new patient share in France and Germany, and [achieving No.1 new patient share in Spain and Italy](#)

◆ **Other progress**

- Launched in Italy (Jul. 2023)
- Approved for HER2 mutant mNSCLC 2L+ and started promotion (Oct. 2023)



Global product sales: FY2023 results **395.9 Bn JPY** (YoY +188.4 Bn JPY) FY2024 forecast **508.4 Bn JPY** (YoY +112.4 Bn JPY)




Japan

- ◆ **Product sales:** FY2023 results **23.9 Bn JPY** FY2024 forecast **25.7 Bn JPY**
- ◆ **Indication:** HER2+ mBC 2L+, HER2 low mBC (post-chemo), HER2+ mGC 3L, HER2 mutant mNSCLC 2L+
- ◆ **Market share status**
 - HER2+ mBC 2L: Maintaining No.1 new patient share
 - HER2 low mBC: Maintaining No.1 new patient share
 - HER2+ mGC 3L: Maintaining No.1 new patient share
 - HER2 mutant mNSCLC 2L: **Achieving No.1 new patient share**
- ◆ **Other progress**
 - Approved for HER2 mutant mNSCLC 2L+ and started promotion (Aug. 2023)
 - Classified as a preferred regimen for HER2 mutant mNSCLC 2L+ treatment in guidelines in Japan (Nov. 2023)

ASCA

- ◆ **Product sales:** FY2023 results **44.6 Bn JPY** FY2023 forecast **64.0 Bn JPY**
- ◆ **Indication:** HER2+ mBC 2L+, HER2 low mBC (post-chemo), HER2+ mGC 2L+, HER2 mutant mNSCLC 2L+
- ◆ **Sales status**
 - Sales growing in Brazil and China
- ◆ **Other progress**
 - China: Launched for HER2+ mBC 2L (Jun. 2023), Approved for HER2 low mBC (post-chemo) and started promotion (Jul. 2023)
 - Brazil: Approved for HER2+ mGC 2L+ and HER2 mutant mNSCLC 2L+ and started promotion (Nov. 2023)



Strategic Collaboration with Merck & Co., Inc., Rahway, NJ, USA

- ◆ **October 2023: Decide co-development and co-commercialization of HER3-DXd, I-DXd, DS-6000**
 - **Maximize the value of 3 products by accelerating and expanding development**
 - **Allocate resource rapidly with flexibility** to new growth drivers following 5DXd ADCs, post DXd ADC modalities, etc.

Development

- ◆ **Co-development** as monotherapy and combination therapy for **HER3-DXd, I-DXd, DS-6000**
- ◆ **MRK*** will be responsible for **75%** of **the first 2 Bn USD** of R&D expenses for each product, and the companies will share R&D expenses **equally thereafter**

Manufacturing

- ◆ **Daiichi Sankyo** will **manufacture** and **supply** all 3 products

Commercial

- ◆ **Global (excluding Japan):**
The companies will **co-promote** and **share gross profit** and **promotional expenses etc.**
- ◆ **Japan:**
Daiichi Sankyo will **solely commercialize** and **pay royalty** to MRK
- ◆ **Sales booking**
Daiichi Sankyo will book product sales in **all countries/regions where Daiichi Sankyo has local operations (including Japan)**

* Merck & Co., Inc., Rahway, NJ, USA

Progress towards “Maximize 3ADCs”


Progress towards “Profit growth for current business and products”

Progress towards “Create shared value with stakeholders”

LIXIANA®: Growth in Each Country/Region



Global revenue FY2023 results: **287.7 Bn JPY (YoY +43.8 Bn JPY)**




LIXIANA®: Growth in Japan

Sales



- ◆ No.1 sales share (FY2023 Q4: **47.2%**)
- ◆ Revenue FY2023 results: **115.6 Bn JPY** (YoY **+10.4 Bn JPY**)



Enhance product portfolio

◆ **VANFLYTA® Anti-Cancer Agent / FLT3 Inhibitor**

- **Approved for acute myeloid leukemia (AML) 1L therapy in May 2023**

Label updated from "relapsed/refractory FLT-ITD positive AML" to "FLT3-ITD positive AML"

◆ **TARLIGE® Orally Disintegrating Tablet** **Pain Treatment**

- **Launched** in May 2023

◆ **DAICHIRONA® FOR INTRAMUSCULAR INJECTION** **COVID-19 vaccine**

- Dec. 2023 **Supply** Omicron XBB.1.5-adapted monovalent vaccine

Enhance transformation into a profit structure focused on patented drugs

◆ **Stock Transfer of DAIICHI SANKYO ESPHA CO., LTD. (Concluded an agreement in May 2023)**

- Transferee: Qol Holdings Co., Ltd.
- Date of transfer: October 1, 2023 (30% of the shares held by the Company), April 1, 2024 (21% of the shares held by the Company)
 - ✕ The date of execution of the transfer of the remaining 49% of the Company's shares will be determined by separate negotiation.
- Consideration for transfer: 25.0 Bn JPY
- Gain on transfer: Approximately 16 Bn JPY will be booked as "Temporary income" in the first quarter of FY2024
- Impacts beyond FY2024:
 - Daiichi Sankyo will be responsible for distribution operations for a certain period
 - Only distribution operations related revenues will be booked as consolidated P&L but not the product sales

US · EU

◆ **Abraxane® (paclitaxel) generic Anti-Cancer Agent**

Launched (US: May 2023)

◆ **VANFLYTA® Anti-Cancer Agent / FLT3 inhibitor for acute myeloid leukemia (AML) 1L therapy**

Launched (US: Aug. 2023, EU: Feb. 2024)

◆ **Nilemdo® / Nustendi® Updates**

- Jan. 2024 DSE and Esperion Therapeutics, Inc. **amended their collaboration** as below
 - for Esperion to transition to DSE manufacturing and supply responsibilities (tech transfer)
 - to expand their collaboration in Europe and other territories, with DSE receiving the full right to the potential development and commercialization of a triple formulation product ^{*1}
 - for DSE to now lead regulatory communications with the European Medicines Agency (EMA) regarding the pending “Cardiovascular outcome trial” label update for Nilemdo/Nustendi
 - for DSE to pay Esperion 100Mn USD after execution of amended agreement, and 25Mn USD after EMA’s decision on pending CLEAR Outcomes study ^{*2} (125Mn USD in total)
 - for Esperion to dismiss the pending litigation against DSE
- ^{*1} bempedoic acid, ezetimibe and a statin
- ^{*2} The trial has been designed to evaluate if bempedoic acid reduces CV events in high- and very high-risk patients who tolerate no or very low doses of statin
- Mar. 2024 **CHMP issued positive opinions** and recommended an update the label as treatments for hypercholesterolemia and significantly reducing cardiovascular events

Progress towards “Maximize 3ADCs”

Progress towards “Profit growth for current business and products”


Progress towards “Create shared value with stakeholders”

FY2023 Annual Dividend Forecast

Increase FY2023 annual dividend forecast per share to 50 JPY due to strong performance of ENHERTU® and others, and upfront payment related to strategic collaboration with MRK*¹ (by 20 JPY compared to FY2022)

Annual Dividend per share

- Year-end Dividend
- Interim Dividend



- **Forecast as of April 2023**
Increase by 4 JPY to 34 JPY compared to FY2022 due to increased likelihood of achieving KPIs for FY2025 driven by sales growth of ENHERTU® and others
- **Forecast as of October 2023**
Increase by 6 JPY to 40 JPY compared to forecast as of April 2023 due to upfront payment related to strategic collaboration with MRK for 3 DXd ADC products, and strong performance of ENHERTU® and others
- **Forecast as of January 2024**
Increase by 10 JPY compared to forecast as of October 2023 to 50 JPY upon FY2023 consolidated forecast revision based on continuous strong business performance and lump sum payment from Novartis following the settlement of Plexxikon's patent infringement lawsuit

*¹ Merck & Co., Inc., Rahway, NJ, USA

Agenda

- ① FY2023 Financial Results
- ② Business Update
- ③ R&D Update**
- ④ 5-Year Business Plan Update
- ⑤ FY2024 Forecast
- ⑥ Appendix



FY2023 R&D major achievements

Realizing the strategic pillars of 5-Year Business Plan “Maximize 3ADC” and “Identify and build pillars for further growth”

5DXd ADCs

ENHERTU®

Dato-DXd

HER3-DXd

I-DXd

DS-6000
(R-DXd)

&

Next Wave

Oncology

Specialty Medicine
& Vaccine

- Expanded ENHERTU® eligible target patients with tumor agnostic indication for HER2 positive solid tumors
- BLA filings were accepted for Dato-DXd and HER3-DXd which demonstrated the wide applicability of DXd ADCs technology platform
- Collaboration with Merck & Co., Inc., Rahway, NJ, USA accelerates and expands the clinical development in HER3-DXd, I-DXd, and DS-6000
- Progress in I-DXd and DS-6000 evolved R&D strategy from “3ADCs and Alpha” to “5DXd ADCs and Next Wave”

- Started combination studies of DXd ADCs and internal assets, i.e., valemestostat and DS-1103
- Progress of quizartinib and valemestostat to potentially address the high unmet needs in hematologic malignancy
- COVID-19 vaccine for Omicron XBB.1.5 strain was approved in Japan

Progress towards “Maximize 3ADCs”


Progress towards “Profit growth for current business and products”

ASCO 2024

News Flow

FDA approved ENHERTU® as the first tumor agnostic HER2 directed therapy in unresectable or metastatic HER2 positive (IHC 3+) solid tumors in Apr 2024*


Objective response and duration of response (ESMO 2023)



Data cut off: Jun 8th, 2023

OS by HER2 status (ESMO 2023)

K-M estimates of OS (All cohorts)



Data cut off: Jun 8th, 2023

Number at risk, month

All cohorts: IHC 3+	75	69	61	56	51	45	39	29	13	4	2	0
All cohorts: IHC 2+	125	113	88	75	62	43	31	22	12	2	0	0
All cohorts: Total	267	239	194	165	143	108	86	65	34	10	4	0

- **ENHERTU® is the first ADC approved for tumor agnostic therapy**
- Demonstrated clinically meaningful and durable responses across a broad range of HER2 expressing advanced solid tumors with consistent safety profile
- **NCCN guidelines have listed ENHERTU® to treat 2L HER2 positive endometrial carcinoma, cervical and ovarian cancers etc.**, based on DESTINY-PanTumor02 study

^a Responses in extramammary Paget's disease, head and neck cancer, oropharyngeal neoplasm, and salivary gland cancer; ^b includes patients with a confirmed objective response only

* Submission data package includes DESTINY-CRC02 and DESTINY-Lung01 study, priority review was granted in US under the RTOR program

BTC: biliary tract cancer, CI: confidence interval, DOR: duration of response, IHC: immunohistochemistry, K-M: Kaplan-Meier, NCCN: National Comprehensive Cancer Network, NR: not reached, ORR: objective response rate, OS: overall survival

Indication expansion in China has been progressing

▶ HER2 low BC* (post chemo)

- Approved in China in Jul 2023, based on DESTINY-Breast04 study data

▶ HER2 positive GC 3L+

- **Filing accepted in China in Dec 2023**, based on DESTINY-Gastric06 study data

▶ HER2 mutant NSCLC 2L+


- **Filing accepted in China in Mar 2024**, based on DESTINY-Lung05 study data

*Note; NDA was approved in China for HER2 positive BC 2L+ in Feb 2023

Bold: update from FY2023 Q3

Filing accepted for nonsquamous NSCLC 2L+ in US (Feb 2024) and EU (Mar 2024), based on the data from TROPION-Lung01 study

PFS in nonsquamous NSCLC (ESMO 2023)



Data cutoff: Mar 2023


- Dato-DXd median PFS: 5.6 months
- Docetaxel median PFS: 3.7 months
- PFS HR for nonsquamous NSCLC without AGAs: 0.71 (0.56, 0.91)
- Manageable safety profile in nonsquamous NSCLC, consistent with the overall population in TROPION-Lung01 study
 - ✓ Low rate of AEs leading to discontinuation of treatment (9%)
 - ✓ Low rate of ILD grade 3+ (2%)
- **PDUFA date: Dec 20th, 2024**

New Ph3 combination study of Dato-DXd and Rilvegostomig* for 1L locally-advanced or metastatic nonsquamous NSCLC

TROPION-Lung10 study design

Key Eligibility

- Stage IIIB-IV nonsquamous NSCLC
- No prior treatment for advanced/metastatic disease
- No AGA
- High PD-L1 expression (TC \geq 50%)



N=675

Dato-DXd 6mg/kg q3w
+ Rilvegostomig q3w

Rilvegostomig q3w

Pembrolizumab q3w

- Compare Dato-DXd in combination with Rilvegostomig or Rilvegostomig monotherapy with Pembrolizumab monotherapy

- Plan to start in 2024 H1

Primary endpoint: PFS and OS in TROP2 BM+
Secondary endpoint: PFS and OS in ITT, ORR, DOR etc.

* Rilvegostomig is a PD-1/TIGIT bispecific antibody in a clinical development by AstraZeneca

AGA: actionable genetic alterations, BM: biomarker, DOR: duration of response, ITT: intention-to-treat, NSCLC: non small cell lung cancer, ORR: objective response rate, OS: overall survival, PFS: progression-free survival, q3w: every 3 weeks, TC: tumor cells

Started a new Ph3 study for 1L EGFR mutated, locally advanced or metastatic nonsquamous NSCLC in Apr 2024

TROPION-Lung14 study design

Key Eligibility

- EGFR mutation (Ex19Del or L858R)
- Locally advanced/metastatic nonsquamous NSCLC
- No prior therapy for advanced disease

R
1:1

N=582

**Osimertinib 80mg QD +
Dato-DXd 6mg/kg x4 q3w**


Osimertinib 80mg QD

Primary endpoint: PFS by BICR
Secondary endpoint: OS, ORR, DOR, DCR, Safety, PK and Immunogenicity etc.


- Ph3 study comparing the efficacy and safety of Osimertinib mono therapy and combination of Osimertinib and Dato-DXd for 1L of **nonsquamous NSCLC with at least one EGFR mutation, Ex19Del or L858R**.

Filing accepted in US, EU, China and Japan for the treatment of HR+/HER2 low or negative BC, based on the data from TROPION-Breast01 study

TROPION-Breast01 in BC development map



TROPION-Breast01 PFS (ESMO 2023)




PFS by investigator assessment: Median 6.9 vs 4.5 months; HR 0.64 (95% CI 0.53–0.76)

Data cutoff: Jul 2023


- Median PFS by BICR: 6.9 months for Dato-DXd (n=365) and 4.9 months for ICC (n=367).
- Final OS data will be analyzed once the target number of events accumulate**
- ILD rate was low; mainly grade 1/2 events. There were one grade 3 and one grade 5 adjudicated ILD event
- Filing accepted in Mar 2024 in Japan, EU and China, followed by in US in Apr 2024 (PDUFA date: Jan 29th, 2025)**

Based on HERTHENA-Lung01 study data, filing accepted with priority review in US for *EGFR*-mutated NSCLC after TKI and platinum-based chemotherapy
Started a new study for expanding indications (HERTHENA-PanTumor01 study)

HER3-DXd development in NSCLC




HERTHENA-PanTumor01 study design



- HERTHENA-Lung01 study demonstrated HER3-DXd efficacy across diverse mechanisms of EGFR TKI resistance and across a broad range of pretreatment tumor HER3 membrane expression.
- Safety profile observed in HERTHENA-Lung01 study was consistent with other HER3-DXd studies
- In Dec 2023 filing accepted and priority review granted in US under the RTOR program. **PDUFA date: Jun 26th, 2024**
- HERTHENA-Lung02 study (Ph3) is in progress to obtain **TLR in FY2024 H2**
- **HERTHENA-PanTumor01 study started in Mar 2024**

Valemetostat combination with DXd ADCs



- Data from this study may form the basis for registrational study (ies)
- Potential new cohorts could be added in the future
- **Started in Feb 2024**

Primary endpoint: Safety, ORR
Secondary endpoint: PFS, OS, DOR,

DS-1103 (anti- SIRPα antibody) combination with DXd ADCs

- **Combination study with ENHERTU®**, targeting HER2-expressing or HER2-mutated solid tumors is **on-going**

Progress towards “Maximize 3ADCs”

Progress towards “Profit growth for current business and products”


ASCO 2024

News Flow

Durable efficacy and manageable safety profile were observed in multiple tumor types and a new Ph3 study in SCLC will start


Efficacy analysis in selected tumor types (ESMO 2023)

SCLC




- cORR: 52.4% (11/21)
(95% CI 29.8–74.3)
- mPFS: 5.6 m (3.9–8.1)
- mOS: 12.2 m (6.4–NE)
- No. of prior treatments, median:
2 (1–7)

ESCC




- cORR: 21.4% (6/28)
(95% CI 8.3–41.0)
- mPFS: 2.8 m (2.1–5.5)
- mOS: 7.0 m (4.8–12.2)
- No. of prior treatments, median:
4 (1–7)

mCRPC



- cORR: 25.4% (15/59)^a
(95% CI 15.0–38.4)
- mPFS: 5.3 m (4.1–6.9)^b
- mOS: 13.0 m (10.3–16.0)^b
- No. of prior treatments, median:
6 (1–11)

squamous NSCLC



- cORR: 30.8% (4/13) (95% CI 9.1–61.4)
- Since enrollment in this cohort is ongoing, analyses of PFS and OS are not yet mature.
- No. of prior treatments, median: 3 (1–12)

■ Ph1/2 study data in SCLC, ESCC, mCRPC, squamous NSCLC were presented at WCLC 2023 and ESMO 2023

Data cutoff: Jan 2023

■ **IDeate-Lung02 study** (Ph3) for relapsed SCLC comparing I-DXd and TPC will start FY2024 H1

a: The ORR is calculated based on 59 patients who received ≥ 1 dose ≥ 4.8 mg/kg, had measurable disease at baseline, ≥ 2 postbaseline scans, and/or discontinued treatment for any reason at data cutoff. b: n=73, including patients with bone metastases who were not evaluable for ORR.

CI: confidence interval, cORR: confirmed objective response rate, ESCC: esophageal squamous cell carcinoma, ESMO: European Society for Medical Oncology, mCRPC: metastatic castration-resistant prostate cancer, mOS: median overall survival, mPFS: median progression-free survival, NE: not estimable, NSCLC: non-small cell lung cancer, ORR: objective response rate, OS: overall survival, PFS: progression-free survival, SCLC: small cell lung cancer, TPC: treatment of physician's choice, WCLC: World Conference on Lung Cancer

Plan to start combination study in 1L in FY2024 H1 to maximize the value of I-DXd in SCLC

IDeate-Lung03 study design (N=149)

Cohort 1

Part A: Maintenance Only

Patients who completed 1L induction
with 4 cycles of SOC without PD

Part B: SOC induction + Maintenance

Treatment naïve ES-SCLC patients

Part A: Safety Run-in

Maintenance

I-DXd
12 mg/kg
+ Atezolizumab
q3w

Part B: Dose Optimization

Induction

Etoposide
+ Atezolizumab
+ Carboplatin

R
1:1

Patients with
CR, PR or SD

Maintenance

Arm 1: I-DXd 8 mg/kg
Arm 2: I-DXd 12 mg/kg

I-DXd
+ Atezolizumab
q3w

Primary endpoint

- Safety

Cohort 2

Induction + Maintenance

Treatment naïve ES-SCLC
patients

Part A: Safety Run-in

Induction

I-DXd
8 mg/kg or
12 mg/kg
+ Atezolizumab
+ Carboplatin
q3w

Maintenance

I-DXd
8 mg/kg or
12 mg/kg
+ Atezolizumab
q3w

Part B: Dose Optimization

Induction

Arm 3: I-DXd 8 mg/kg
Arm 4: I-DXd 12 mg/kg

I-DXd
+ Atezolizumab
+ Carboplatin
q3w

Maintenance


Arm 3: I-DXd 8 mg/kg
Arm 4: I-DXd 12 mg/kg

I-DXd
+ Atezolizumab
q3w

Secondary endpoint


- PFS, ORR, DOR, etc

Plan to start a new signal seeking Ph2 study in multiple cancers to investigate further possibility of I-DXd



Promising data were obtained in platinum resistant ovarian cancer and new Ph2/3 study started

Efficacy in Ph1 study (SGO 2024)



Data Cutoff: July 2023

- DS-6000 demonstrated strong clinical activity and manageable safety profile in Ph1 study platinum resistant ovarian cancer cohort
- **REJOICE-Ovarian01 study (Ph2/3)** for platinum resistant ovarian, primary peritoneal or fallopian tube cancer **started in Apr 2024** based on the data from Ph1 study

Providing new treatment options addressing high unmet medical needs

▼ VANFLYTA®

- **Approved in countries and regions** shown below based on QuANTUM-First study (Ph3) for *FLT3*-ITD positive AML 1L
 - May 2023: Japan
 - Jul 2023: US
 - Nov 2023: EU

▼ Valemetostat (Brand name in Japan: EZHARMIA®)

- VALENTINE-PTCL01 study (Ph2) data were presented at ASH2023. monotherapy of valemetostat demonstrated high ORR (43.7%) and manageable safety profile in patients with relapsed/ refractory PTCL
- **Filing accepted in Japan** in Jan 2024 based on the VALENTINE-PTCL01 **and regulatory decision is anticipated in FY2024 H1**

Oncology

- ◆ **DS-3939** (TA-MUC1 directed ADC)
 - Ph1/2 study for solid tumors started in Sep 2023
- ◆ **DS-1471** (anti-CD147 antibody)
 - Ph1 study for solid tumors started in Sep 2023
- ◆ **DS-1594** (Menin-MLL binding inhibitor, AML and ALL)
 - **Development discontinued**

Vaccine

- ◆ **DAICHIRONA® FOR INTRAMUSCULAR INJECTION***
(COVID-19 vaccine)
 - Vaccine for original strain was approved in Japan in Aug 2023
 - Vaccine for Omicron XBB.1.5 strain was approved in Japan in Nov 2023
- ◆ **VN-0102/JVC-001** (mixed measles-mumps-rubella vaccine)
 - **Filing accepted in Japan in Mar 2024**

Specialty Medicine

- ◆ **DS-1211** (TNAP inhibitor, PXE)
 - **Positive TLR from Ph2 study in Apr 2024**
- ◆ **DS-7011** (anti-TLR7 antibody, SLE)
 - Ph1b/2 study for SLE patients started in Jul 2023
- ◆ **DS-2325** (KLK5 inhibitor, Netherton syndrome)
 - Rare pediatric disease designation was granted in US in May 2023
 - Ph1b/2 study in Netherton syndrome patients started in Dec 2023

Bold: update from FY2023 Q3

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, PXE: pseudoxanthoma elasticum, SLE: systemic lupus erythematosus, TLR: Top Line Results

* The research and development of DAICHIRONA® FOR INTRAMUSCULAR INJECTION is being conducted through the "Vaccine development project" promoted by the Japan Agency for Medical Research and Development (AMED) and the "Urgent improvement project for vaccine manufacturing systems" supported by the Japanese Ministry of Health, Labour and Welfare (MHLW).

Progress towards “Maximize 3ADCs”

Progress towards “Profit growth for current business and products”

ASCO 2024

News Flow

ASCO Highlight 2024: IR conference call



Hiroyuki Okuzawa
President and COO



Ken Takeshita
Head of Global R&D



Mark Rutstein
Head of Global Oncology
Development

Date and Time

Jun 4, 2024 (Tue) 8:00-9:00am JST/
Jun 3, 2024 (Mon) 6:00-7:00pm CDT

Meeting style

Virtual (Zoom)

Content will be delivered on-demand after the meeting

Progress towards “Maximize 3ADCs”

Progress towards “Profit growth for current business and products”

ASCO 2024

News Flow

Planned major publications

American Society of Clinical Oncology (ASCO, May 31-Jun 4, 2024)

ENHERTU®	DESTINY-Breast03: HER2+ BC, 2L, Ph3 • Updated OS data
	DESTINY-Breast07: HER2+ BC, 1L, Ph1b/2 • ENHERTU® ±pertuzumab dose expansion phase interim analysis results
	DESTINY-Lung02: HER2 mutant NSCLC, 2L+, Ph2 • Final analysis results
	DESTINY-PanTumor02: HER2+ solid tumors, 2L+, Ph2 • BTC and pancreatic cancer • Bladder cancer • Head and neck tumors

Dato-DXd	TROPION-Lung02: NSCLC, pembrolizumab combo, Ph1 • Data update
----------	---

Regulatory decisions

ENHERTU®	DESTINY-Gastric06: HER2+ GC, 3L+ • CN: FY2024 H1
	DESTINY-Lung05: HER2 mutant NSCLC, 2L+ • CN: FY2024 H2

Dato-DXd	TROPION-Lung01: NSCLC, 2/3L • US : FY2024 H2
	TROPION-Breast01: HR+ and HER2 low or negative BC, 2/3L • JP/US: FY2024 H2

Regulatory decisions

HER3-DXd	HERTHENA-Lung01: EGFR mutated NSCLC, 3L • US: FY2024 H1
----------	---

Valemetostat	VALENTINE-PTCL01 : r/r PTCL • JP: FY2024 H1
--------------	---

Key data readouts

ENHERTU®	DESTINY-Breast06* : HR+/HER2 low BC, chemo naïve, Ph3 • FY2024 H1
	DESTINY-Breast11 : HER2+ BC, neoadjuvant, Ph3 • FY2024 H2

Dato-DXd	TROPION-Breast02* : PD-1/PD-L1 ineligible TNBC, 1L, Ph3 • FY2024 H2
----------	--

HER3-DXd	HERTHENA-Lung02* : EGFR mutated NSCLC, 2L, Ph3 • FY2024 H2
----------	---

BC: breast cancer, BTC: biliary tract cancer, CN: China, GC: gastric cancer, HR: hormone receptor, NSCLC: non-small cell lung cancer, OS: overall survival, PTCL: peripheral T cell lymphoma, r/r: relapsed/refractory, TNBC: triple-negative breast cancer

Bold: update from FY2023 Q3

Timeline indicated is based on the current forecast and subject to change

※ Timeline for “Planned regulatory filing” indicates expected filing acceptance date

*: event-driven study

Agenda

- ① FY2023 Financial Results
- ② Business Update
- ③ R&D Update
- ④ **5-Year Business Plan Update**
- ⑤ FY2024 Forecast
- ⑥ Appendix



Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025)

Realize 2025 Goal and Shift to Further Growth

FY2025

Financial Targets

- ◆ Revenue: 1.6 Tr JPY (Oncology > 600.0 Bn JPY)
- ◆ Core Operating Profit* Ratio before R&D Expense: 40%
- ◆ ROE > 16%
- ◆ DOE** > 8%

Maximize 3ADCs

- ◆ Maximize ENHERTU® and Dato-DXd through strategic alliance with AstraZeneca
- ◆ Maximize HER3-DXd without a partner
- ◆ Expand work force and supply capacity flexibly depending on changes around product potential

Profit growth for current business and products

- ◆ Maximize Lixiana® profit
- ◆ Grow Tarlige®, Nilemdo®, etc. quickly
- ◆ Transform to profit structure focused on patented drugs
- ◆ Profit growth for American Regent and Daiichi Sankyo Healthcare

Identify and build pillars for further growth

- ◆ Identify new growth drivers following 3ADCs
- ◆ Select and advance promising post DXd-ADC modalities

Create shared value with stakeholders

- ◆ Patients: Contributing to patients through "Patient Centric Mindset"
- ◆ Shareholders: Balanced investment for growth and shareholder returns
- ◆ Society: Environment load reduction across the value chain, and actions against pandemic risks
- ◆ Employees: Create one DS culture through fostering our core behaviors

- ◆ Data-driven management through DX, and company-wide transformation through advanced digital technology
- ◆ Agile decision making through new global management structure

*Excluding temporary income and expenses (gains/losses related to sales of fixed assets etc.) from operating income

**DOE: Dividend on Equity = Total dividend amount / Equity attributable to owners of the company

5-Year Business Plan: Progress in FY2021-FY2023

Maximize 3ADCs

- ◆ **Maximize product value of ENHERTU®**
 - **Approval of new indication**
 - HER2+ BC 2L, HER2 low BC post-chemo, HER2 mutant NSCLC 2L+, HER2+ Solid Tumors 2L+ etc.
 - **Sales growth in each country/region**
 - **Progress of indication expansion**
 - HER2+ BC 1L (DB-09), HER2+ BC neoadjuvant (DB-11), HER2 low BC chemo naïve (DB-06) etc.
- ◆ **Maximize product values of Dato-DXd and HER3-DXd**
 - **Filing accepted**
 - Dato-DXd : Non SQ NSCLC 2L+ (TL-01)
HR+/HER2 low or negative BC 2L (TB-01)
 - HER3-DXd : EGFR mutated NSCLC 3L (HL-01)
 - **Initiation of new Ph3 studies**
 - Dato-DXd : NSCLC (without actionable genomic alteration) 1L (TL-07 and TL-08) etc.
 - HER3-DXd : EGFR mutated NSCLC 2L (HL-02) etc.
- ◆ **Strategic collaboration for HER3-DXd, I-DXd and DS-6000**
 - **Co-development and co-commercialization with MRK^{*1}**

Profit growth for current business and products

- ◆ **Growth of current products**
 - **Steady sales expansion of Lixiana®**
 - Increase product value with additional dosage and administration^{*2}
 - **Sales increase of current products in each country/region**
 - Tarlige®, Venofer®, Nilemdo®/Nustendi® etc.
 - Increase product values of current products by additional indication/formulation
- ◆ **Transformation of business structure focused on patented drugs**
 - **Launch of new drug**
 - Emgality®, Ezharmia®, Vanflyta®, Daichirona® etc.
 - **Progress of product divestiture after loss of exclusivity in each country/region**
 - **Stock transfer of Daiichi Sankyo Espha Co., Ltd.**
 - Divestiture of generic business in Japan
- ◆ **Profit growth for American Regent and Daiichi Sankyo Healthcare**
 - **Contribution to consolidated performance through increased revenue and profit.**

^{*1} Merck & Co., Inc., Rahway, NJ, USA

^{*2} Prevention for stroke and systemic embolism in elderly patients with non-valvular atrial fibrillation and high bleeding risk: ELDERCARE-AF study

5-Year Business Plan: Progress in FY2021-FY2023

Identify and build pillars for further growth

- ◆ **Emerging growth drivers following 3ADCs**
 - **Progress of development for I-DXd (B7-H3-directed ADC)**
 - Accumulated promising data in Ph1/2 study for multiple cancer types
 - Plan to start Ph3 study for SCLC
 - Accelerate development through strategic collaboration with MRK
 - **Progress of development for DS-6000 (CDH6-directed ADC)**
 - Accumulated promising data for OVC
 - Accelerate development through strategic collaboration with MRK
- ◆ **Advancement to select post DXd-ADC modalities**
 - **Started clinical study for 2nd generation ADC, DS-9606**
 - **Approval and supply of mRNA COVID-19 vaccine, Daichirona® for intramuscular injection**

OVC: ovarian cancer, SCLC: small cell lung cancer,,

Create shared value with stakeholders

- ◆ **Strengthening shareholder returns**
 - **Increase dividend taking account of profit growth**
 - Increase annual dividend in two consecutive years due to profit growth of ENHERTU®, and received upfront payment related to strategic collaboration with MRK etc
- ◆ **Actions against pandemic risks**
 - **Supply of Daichirona® for intramuscular injection (Omicron XBB.1.5-adapted monovalent vaccine)**
 - Submitted approval application for original strain booster vaccination
- ◆ **Environment load reduction across the value chain**
 - **Progress initiative for environmental issues**
 - Joined RE100, a global initiative aiming to use 100% renewable energy for electricity consumed in business activities
 - Converted electricity consumed in bases in Japan to renewable energy
- ◆ **Penetration of Core Behavior for fostering one DS culture**
 - **Further understanding of three Core Behaviors through workshop by management and employees**

Estimate for FY2025 KPIs

(as of Apr. 2024)


	5YBP Target (Apr. 2021)	Estimate as of Apr. 2023	Estimate as of Apr. 2024
Revenue	1,600 Bn JPY	2.0 Tr JPY	2.1 Tr JPY
Revenue in Oncology	> 600 Bn JPY	> 900 Bn JPY	> 1.0 Tr JPY
Core Operating Profit ratio before R&D expense	40%	40%	40%
ROE	> 16%	> 16%	> 16%
DOE	> 8%	> 8%	> 8.5%
Currency rate assumptions	1 USD=105 JPY, 1 EUR=120 JPY	1 USD=130 JPY, 1 EUR=140 JPY	1 USD=145 JPY, 1 EUR=155 JPY

Estimated Oncology Revenue

(as of Apr. 2024)

Estimate **oncology revenue of 1 Tr JPY or more in FY2025** driven by further revenue growth of ENHERTU® and upfront payments related to strategic collaboration with MRK*¹ for HER3-DXd, I-DXd, and DS-6000

Image for consolidated oncology revenue growth



Increase/decrease from Apr. 2023 estimation

Major Increase

◆ ENHERTU®

✓ Further revenue growth in breast cancer driven by DB-03/04 indications

◆ ◆ HER3-DXd, I-DXd, DS-6000

✓ Revenue increase from upfront payments related to strategic collaboration with Merck

Major decrease

◆ Dato-DXd

✓ Revised target patient population based on TL-01 results

✓ Revised timeline for TL-08

*1 Merck & Co., Inc., Rahway, NJ, USA

*2 Revenue for ENHERTU®, Dato-DXd, HER3-DXd, I-DXd and DS-6000 includes alliance revenue (50% of gross profit from product sales in countries/regions where AstraZeneca and Merck book sales), upfront payments, development and sales milestones received from both collaborators based on strategic alliance agreements

Estimated R&D Expenses


(as of Apr. 2024)

Estimate **R&D expenses of approx. 1 Tr JPY for FY2024 and FY2025** in total driven by new study initiation for ENHERTU® and other expenses

R&D expenses trend

■ as of Apr. 2023^{*1}

■ as of Apr. 2024^{*2}



Currency rate assumptions
^{*1}: 1USD=130 JPY, 1EUR=140 JPY
^{*2}: 1USD=145 JPY, 1EUR=155 JPY

Forecast
^{*3}: as of Apr. 2023
^{*4}: as of Apr. 2024

Increase/decrease from Apr. 2023 estimation

Major Increase

- ◆ **Initiation of new studies for ENHERTU®**
 - ✓ New studies considering DPT-02 results
- ◆ **Acceleration of indication expansion studies and initiation of new studies for Next Wave products** (DS-3939, etc.)
- ◆ **Expanded medical affairs activities** (Create and deliver new evidence for ENHERTU®, Dato-DXd and HER3-DXd)
- ◆ **Strengthen R&D infrastructure** (Increased R&D headcount)

Major decrease

- ◆ **HER3-DXd, I-DXd, DS-6000**
 - ✓ Acceleration of indication expansion studies and initiation of new studies through the strategic collaboration with Merck^{*1} (IDeate-Lung02, REJOICE-Ovarian01, etc.)
 - ✓ Meanwhile, Daiichi Sankyo's R&D expenses for these three ADCs will decrease from the cost share with Merck
(Merck will be responsible for 75% of the first 2 Bn USD of R&D expenses for each product, and the companies will share R&D expenses equally thereafter)


^{*1} Merck & Co., Inc., Rahway, NJ, USA

Well-balanced Investment for Growth and Shareholder Returns

Cash Allocation

Increase **R&D expense** and **CAPEX** for further growth in future, and increase **shareholder returns** with cash flow of **approx. 600.0 Bn JPY** increased due to the received upfront payment related to strategic collaboration with MRK etc.

Image for cash allocation
(Comparison with as of April 2023)



Forecast of FY2025 KPIs


(as of Apr. 2024)

◆ Revenue

2.0 Tr JPY

➤ **Revenue in Oncology**
> 1 Tr JPY

Achieve significant revenue/profit growth after investment for DXd ADCs, and shift to a new stage for realizing 2030 vision



Forecast of Core Operating Profit* ratio before R&D expense: 39%

◆ **Core Operating Profit* ratio before R&D expense: 40%**

◆ **ROE > 16%**


◆ **DOE > 8.5%**

FY2025 Currency rate assumptions: 1 USD=**145 JPY**, 1 EUR=**155 JPY**

*Excluding temporary income and expenses (gains/losses related to sales of fixed assets etc.) from operating income




Daiichi Sankyo will contribute to the enrichment of quality of life around the world



Agenda

- ① FY2023 Financial Results
- ② Business Update
- ③ R&D Update
- ④ 5-Year Business Plan Update
- ⑤ **FY2024 Forecast**
- ⑥ Appendix



FY2024 Forecast

(Bn JPY)

	FY2023 Results	FY2024 Forecast	vs. Forecast
Revenue	1,601.7	1,750.0	+148.3
Cost of sales *1	414.8	395.0	-19.8
SG&A expenses *1	627.3	675.0	+47.7
DXd ADC profit share *2	170.6	193.6	+23.0
Other SG&A expenses	456.8	481.4	+24.6
R&D expenses *1	364.3	470.0	105.7
Core operating profit *1	195.3	210.0	+14.7
Temporary income *1	27.3	20.0	-7.3
Temporary expenses *1	10.9	-	-10.9
Operating profit	211.6	230.0	+18.4
Profit before tax	237.2	235.0	-2.2
Profit attributable to owners of the Company	200.7	190.0	-10.7

Currency	USD/JPY	144.62	145.00	+0.38
Rate	EUR/JPY	156.79	155.00	-1.79

Revenue

Increase factor ▲ Sales expansion of main products (Enhertu, Lixiana, Tarlige, etc.)
Deferred revenue increase from upfront payments related to strategic collaboration with Merck

Decrease Factor ▼ DS Espha product (Impact of stock transfer), Drug price revision

Cost of sales

Decrease due to improvement in cost of sales ratio through changing in product mix

SG&A expenses

- Increase in profit share due to sales expansion of Enhertu
- Increase due to intensive resource allocation to the oncology business, strategic investments in DX/IT and human capital for long-term growth

R&D expenses

Increase due to increased R&D investment focused on 5DXd ADCs, expanded medical affairs activities and strengthen R&D infrastructure (Increased R&D headcount)

Temporary expenses

FY2023: Lump sum payment for the settlement of patent infringement lawsuit in US etc.
FY2024: Gain on stock transfer of DS Espha etc.

Profit before tax

Decrease in interest income and others due to the decrease financial assets in US dollar

Profit attributable to owners of the Company

FY2023 Tax Rate: 15.3% (Impact of Tax credit for R&D expenses and stock transfer of DS Espha etc.)

FY2024 Tax Rate: approx. 19% (Impact of Tax credit for R&D expenses etc.)

*1 As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed. Income and expenses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses". Temporary income and expenses are excluded from results and forecast for cost of sales, SG&A expenses and R&D expenses shown in the list above. The adjustment table from operating profit to core operating profit is stated in the reference data.

*2 DS pays alliance partners 50% of gross profit for the product sales in countries/regions where DS book revenue (excluding Japan) to share profit with the partners.

FY2024 Annual Dividend Forecast


Increase annual dividend per share from 50 JPY (FY2023) **to 60 JPY (FY2024)**

taking account of increasing probability of achieving FY2025 KPIs following further sales expansion of Enhertu®

Annual dividend per share in FY2024: 60 JPY (interim dividend: 30 JPY, year-end dividend: 30 JPY)

Annual Dividend per share

- Year-end Dividend
- Interim Dividend



Flexible Acquisition of Own Shares

- ◆ Decided **acquisition** and **cancellation of own shares** for shareholder returns enhancement and capital efficiency improvement
- ◆ **FY2025 DOE is expected over 8.5%** which exceeds the original target

Acquisition


- Acquisition period: **Apr. 26, 2024 – Jan. 15, 2025**
- Aggregate amount of acquisition cost: **200 billion JPY** (maximum)
- Total number of shares to be acquired: **55 million stocks** (maximum)

Cancellation

- Cancellation date: **Jan. 31, 2025**
- Number of shares to be cancelled: **All of acquired own shares**

Agenda

- ① FY2023 Financial Results
- ② Business Update
- ③ R&D Update
- ④ 5-Year Business Plan Update
- ⑤ FY2024 Forecast
- ⑥ **Appendix**



3ADCs launch plan

Realize maximizing the product values of 3ADCs
through expanding the indications

5-Year Business Plan (FY2021-FY2025)

FY2026 & Beyond

ENHERTU®



DESTINY-Breast05



DESTINY-Gastric04

- Combo with DS internal asset, I/O or targeted therapy in BC and NSCLC
- Other cancer types

Dato-DXd



TROPION-Lung07



TROPION-Lung08



TROPION-Breast03

- Combo with I/O in BC and NSCLC etc.
- Other cancer types

HER3-DXd

- Combo with targeted therapy in NSCLC
- Other cancer types

Dato-DXd



TROPION-Lung01



TROPION-Breast01



TROPION-Breast02

HER3-DXd



HERTHENA-Lung01



HERTHENA-Lung02

ENHERTU®



DESTINY-Breast03



DESTINY-Breast04



DESTINY-Breast06



DESTINY-Breast09



DESTINY-Breast11



DESTINY-Gastric02



DESTINY-Lung01/02



DESTINY-Lung04



DESTINY-PanTumor02*

~FY2020

ENHERTU®



DESTINY-Breast01



DESTINY-Gastric01

Major study only (ref., appendices)



Already approved indications



Studies with updated timeline from the estimation in Apr 2023

* Submission data package includes DESTINY-CRC02 and DESTINY-Lung01 study
Timeline indicated is based on the current forecast and subject to change.

ADC: antibody-drug conjugate, BC: breast cancer, I/O: immuno-oncology, NSCLC: non-small cell lung cancer

Major R&D Milestones (ENHERTU®)

As of Apr 2024

Project	Target indication [phase, study name]	FY2023	FY2024	
		H2	H1	H2
ENHERTU®	BC • HR+/HER2 low, chemo naive [Ph3, DESTINY-Breast06]		• TLR anticipated	
	• HER2+, neoadjuvant [Ph3, DESTINY-Breast11]			• TLR anticipated
	GC • HER2+, 3L+ [Ph2, DESTINY-Gastric06]	• Filing accepted (CN)	• Regulatory decision anticipated (CN)	
	NSCLC • HER2 mutant, 2L [Ph2, DESTINY-Lung05]	• TLR obtained • Filing accepted (CN)		• Regulatory decision anticipated (CN)
	Other tumors • HER2 expressing tumors [Ph2, DESTINY-PanTumor02]	• Filing accepted (US)	• Approval (US)	

Bold: update from FY2023 Q3

BC: breast cancer, GC: gastric cancer, HR: hormone receptor, NSCLC: non small cell lung cancer, TLR: top line results
Timeline indicated is based on the current forecast and subject to change

Major R&D Milestones (Dato-DXd)

As of Apr 2024

Project	Target indication [phase, study name]	FY2023	FY2024	
		H2	H1	H2
Dato-DXd	• 2/3L [Ph3, TROPION-Lung01]	• Filing accepted (US, EU)		• Regulatory decision anticipated (US)
	• 1L, nonsquamous, PD-L1 high, rilvegostomig combo [TROPION-Lung10]		• Study start planned	
	• 1L, nonsquamous, EGFR mutated, osimertinib combo [Ph3, TROPION-Lung14]		• Study start planned	
	• HR+ and HER2 low or negative, 2/3L [Ph3, TROPION-Breast01]	• Filing accepted (JP, EU, CN)	• Filing accepted (US)	• Regulatory decision anticipated (JP, US)
	• TNBC, PD-1/PD-L1 ineligible, 1L [Ph3, TROPION-Breast02]			• TLR anticipated
	• TNBC or HR low, HER2 low or negative BC, neoadjuvant/adjuvant [Ph3, TROPION-Breast04]	• Study started		
	• TNBC, PD-L1 positive, 1L [Ph3, TROPION-Breast05]	• Study started		

Bold: update from FY2023 Q3

BC: breast cancer, HR: hormone receptor, NSCLC: non-small cell lung cancer, TLR: top line results, TNBC: triple-negative breast cancer

Timeline indicated is based on the current forecast and subject to change

Major R&D Milestones (HER3-DXd, I-DXd, DS-6000)

As of Apr 2024

Project		Target indication [phase, study name]	FY2023	FY2024	
			H2	H1	H2
HER3-DXd	NSCLC	• EGFR mutant, 3L [Ph2, HERTHENA-Lung01]	• Filing accepted (US)	• Regulatory decision anticipated (US)	
		• EGFR mutant, 2L [Ph3, HERTHENA-Lung02]			• TLR anticipated
	Other tumors	• Melanoma, SCCHN, HER2 negative GC [Ph2, HERTHENA-PanTumor01]	• Study started		
I-DXd	SCLC	• 2L+ [Dose optimization, Ph2, IDEate-Lung01]			• TLR anticipated
		• 2L+ [Ph3, IDEate-Lung02]		• Study start planned	
		• 1L [Ph1b/2, IDEate-Lung03]		• Study start planned	
	Other tumors	• Endometrial cancer, SCCHN, etc [Ph2, IDEate-PanTumor02]		• Study start planned	
DS-6000 (R-DXd)	OVC	• 2L+ [Ph2/3, REJOICE-Ovarian01]		• Study started	

Bold: update from FY2023 Q2

GC: gastric cancer, NSCLC: non-small cell lung cancer, OVC: ovarian cancer, SCCHN: squamous cell carcinoma of the head and neck, SCLC: small cell lung cancer, TLR: top line results

Timeline indicated is based on the current forecast and subject to change

Major R&D Milestones (Next Wave)

As of Apr 2024

Project	Target indication [phase, study name]	FY2023 H2	FY2024	
			H1	H2
valemestostat	• r/r PTCL [Registrational Ph2, VALENTINE-PTCL01]	• Filing accepted (JP)	• Regulatory decision anticipated (JP)	
	• HER2+ GC, non-squamous NSCLC [Ph1b、 ENHERTU®, Dato-DXd combo]	• Study started		
DAICHIRONA®	• COVID-19 mRNA vaccine (mutant strain), Children aged 5 to 11 years [Ph2/3]	• TLR obtained	• Planned regulatory filing※ (JP)	
MMR vaccine (VN-0102)	• mixed measles-mumps-rubella vaccine [JP]	• Filing accepted (JP)		

Bold: update from FY2023 Q3

GC: gastric cancer, NSCLC: non-small cell lung cancer, PTCL: peripheral T cell lymphoma, r/r: relapsed/refractory, TLR: top line results

Timeline indicated is based on the current forecast and subject to change

※ Timeline for "Planned regulatory filing" indicates expected filing acceptance date



Major R&D Pipeline: 5DXd ADCs

As of Apr 2024

Phase 1		Phase 2	Phase 3		Regulatory phase
(US/EU/Asia) HER2+ BC 2L+/1L DESTINY-Breast07	(JP/US/EU/Asia) NSCLC (w/o AGA, pembrolizumab combo) TROPION-Lung02	(CN) HER2 expressing solid tumors DESTINY-PanTumor03	(JP/US/EU/Asia) HER2+ BC adjuvant* ¹ DESTINY-Breast05	(JP/US/EU/Asia) in prep PD-L1 high nonsquamous NSCLC (w/o AGA, rilvegostomig combo) 1L TROPION-Lung10	(CN) HER2+ GC 3L DESTINY-Gastric06
(US/EU/Asia) HER2 low BC Chemo naïve/post chemo DESTINY-Breast08	(JP/US/EU) NSCLC (w/o AGA, durvalumab, rilvegostomig, volrustomig and sabestomig combo) TROPION-Lung04	(JP/US/EU/Asia) solid tumors TROPION-PanTumor03	(JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06	(JP/US/EU/Asia) in prep EGFR mutated NSCLC (osimertinib combo) 1L TROPION-Lung14	(CN) HER2 mutant NSCLC 2L+ DESTINY-Lung05
(JP/US/EU/Asia) HER2+ GC combo, 2L+/1L DESTINY-Gastric03	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia) EGFR mutated NSCLC (osimertinib combo) 2L ORCHARD	(JP/US/EU/Asia) HER2+ BC 1L DESTINY-Breast09	(JP/US/EU/Asia) TNBC (PD-1/PD-L1 inhibitor ineligible) 1L TROPION-Breast02	(US/EU) NSCLC 2/3L TROPION-Lung01
(US/EU/Asia) HER2+ NSCLC (durvalumab, volrustomig combo) 1L DESTINY-Lung03	(JP/US/EU/Asia) solid tumors (saruparib combo) PETRA	(US/EU/Asia) resectable early-stage NSCLC (durvalumab combo) neoadjuvant NeoCOAST-2	(JP/US/EU/Asia) HER2+ BC neoadjuvant DESTINY-Breast11	(JP/US/EU/Asia) TNBC adjuvant* ² (mono or durvalumab combo) TROPION-Breast03	(JP/US/EU/CN) BC* ³ 2/3L TROPION-Breast01
(US/EU) BC, NSCLC (pembrolizumab combo)	(JP/US/EU/Asia) NSCLC	(JP/US/EU/Asia) melanoma, SCCHN, HER2 negative GC, 2L+ HERTHENA-PanTumor01	(JP/EU/Asia) HER2+ GC 2L DESTINY-Gastric04	(JP/US/EU/Asia) TNBC neoadjuvant and adjuvant (durvalumab combo) TROPION-Breast04	(US) EGFR mutated NSCLC 3L HERTHENA-Lung01
(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/Asia) EGFR mutated NSCLC, 1/2L (osimertinib combo)	(JP/US/EU/Asia) ES-SCLC, 2L+ IDeate-Lung01	(JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or exon 20 mutation) 1L DESTINY-Lung04	(JP/US/EU/Asia) PD-L1 positive TNBC 1L (mono or durvalumab combo) TROPION-Breast05	
(US/EU/Asia) solid tumors (saruparib combo) PETRA	(JP/US) ESCC, CRPC, squamous NSCLC, SCLC, etc. IDeate-PanTumor01	(JP/US/EU/Asia) solid tumors, 2L+ IDeate-Lung01	(JP/US/EU/Asia) nonsquamous NSCLC (w/o AGA, pembrolizumab combo) 1L TROPION-Lung07	(JP/US/EU/Asia) EGFR mutated NSCLC 2L HERTHENA-Lung02	
(JP/US) solid tumors TROPION-PanTumor01	(JP/US/EU/Asia) in prep ES-SCLC, 1L IDeate-Lung03	(JP/US/EU/Asia) ovarian cancer REJOICE-Ovarian01	(JP/US/EU/Asia) NSCLC (w/o AGA, pembrolizumab combo) 1L TROPION-Lung08	(JP/US/EU/Asia) in prep ES-SCLC, 2L+ IDeate-Lung02	
(CN) NSCLC, TNBC TROPION-PanTumor02	(JP/US) renal cell carcinoma, ovarian cancer				

 ENHERTU® (T-DXd)
  Dato-DXd
  HER3-DXd
  I-DXd
  DS-6000 (R-DXd)

 Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials

 Breakthrough Designation (US)
  Orphan drug designation (designated in at least one country/region among JP, US and EU)

- * 1 Adjuvant therapy for HER2 positive breast cancer patients with residual invasive disease following neoadjuvant therapy
- * 2 Adjuvant therapy for TNBC patients with residual invasive disease following neoadjuvant therapy
- * 3 HR+, HER2 low or negative BC

AGA: actionable genomic alterations, BC: breast cancer, CRC: colorectal cancer, CRPC: castration-resistant prostate cancer, ESCC: esophageal squamous cell carcinoma, ES-SCLC: extensive stage-small cell lung cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCCHN: squamous cell carcinoma of head and neck, SCLC: small cell lung cancer, TNBC: triple negative breast cancer

Major R&D Pipeline: Next Wave



As of Apr 2024

Phase 1		Phase 2	Phase 3	Regulatory phase
DS-1055 (JP/US) Anti-GARP antibody Solid tumors	DS-7011 (US) Anti-TLR7 antibody Systemic lupus erythematosus	Valemetostat (EU) EZH1/2 inhibitor BCL	Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor	Valemetostat (JP) EZH1/2 inhibitor PTCL
DS-9606 (US/EU) Target undisclosed ADC Solid tumors	DS-2325 (EU) KLK5 inhibitor Netherton syndrome	DS-1001 (JP) Mutant IDH1 inhibitor Glioma	Esaxerenone (JP) MR blocker Diabetic nephropathy	Mirogabalin (CN) α2δ ligands Diabetic peripheral neuropathic pain
DS-1103 Anti-SIRPα antibody HER2 expressing or mutant solid tumors, HER2 low BC		DS-1211 (US/EU) TNAP inhibitor Pseudoxanthoma elasticum	DS-5670 (JP) COVID-19 mRNA vaccine (mutant strain), COVID-19 (booster vaccination, 5 to 11 aged children)	VN-0102/JVC-001 (JP) Mixed measles-mumps-rubella vaccine
DS-3939 Anti-TA-MUC1 ADC Solid tumors		VN-0200 (JP) RS virus vaccine RS virus infection	DS-5670 (JP) COVID-19 mRNA vaccine (mutant strain), COVID-19 (single dose, 12 years old and over)	
DS-1471 Anti-CD147 antibody Solid tumors				
Valemetostat EZH1/2 inhibitor, HER2+ GC (ENHERTU® combo) and NSQ NSCLC (Dato-DXd combo)				

- Oncology
- Specialty medicine
- Vaccine
- Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
- SAKIGAKE Designation (JP)
- Orphan drug designation (designated in at least one country/region among JP, US and EU)
- Rare Pediatric Disease Designation (US)
- Fast Track Designation (US)

ALL: acute lymphoblastic leukemia, BCL: B cell lymphoma, LBCL: large B cell lymphoma, PTCL: peripheral T-cell lymphoma

Contact address regarding this material

Daiichi Sankyo Co., Ltd.

Corporate Communications Department

TEL: +81-3-6225-1125

Email: DaiichiSankyoIR@daiichisankyo.co.jp